ArticleJPEN. Journal of parenteral and enteral nutrition2025
Central line-associated bloodstream infection rates in pediatric short bowel syndrome in the United States: A retrospective cohort study from 2016 to 2023.
Article in JPEN. Journal of parenteral and enteral nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCentral line-associated bloodstream infections (CLABSIs) are the leading cause of hospitalization in pediatric short bowel syndrome, disproportionately impacting socioeconomically disadvantaged children. We examined changes in overall CLABSI rates over time and assessed whether socioeconomic disparities persist.
methodsUsing the Pediatric Health Information System database, we studied short bowel syndrome patients aged <18 years hospitalized between 2015 and 2023. Patients were stratified into neighborhood income groups based on zip code-based median household income. CLABSI rates were assessed with mixed-effects Poisson regression over four eras (2016-2017, 2018-2019, 2020-2021, 2022-2023).
resultsOf 8772 hospitalizations of 2048 children with short bowel syndrome at 43 institutions, CLABSI was the principal diagnosis for 30% of hospitalizations. Univariable analysis showed decreased CLABSI rates during 2018-2019 (rate ratio [RR] 0.71, 95% CI 0.63-0.81; P < 0.001), 2020-2021 (RR 0.66, 95% CI 0.57-0.75; P < 0.001), and 2022-2023 (RR 0.60, 95% CI 0.52-0.70; P < 0.001), relative to 2016-2017. In multivariable analyses, 2022-2023 was associated with lower CLABSI rates relative to 2016-2017 (RR 0.61, 95% CI 0.52-0.70; P < 0.001). Low neighborhood income (RR 1.59, 95% CI 1.14-2.21; P < 0.001), public insurance (RR 1.59, 95% CI 1.37-1.84; P < 0.001), and non-Hispanic Black race (RR 1.19, 95% CI 1.01-1.39; P = 0.03) were associated with higher CLABSI rates relative to high neighborhood income, private insurance, and non-Hispanic White race, respectively.
conclusionCLABSI rates in pediatric short bowel syndrome have decreased over the past 8 years, yet socioeconomic and racial disparities persist. Efforts to prevent CLABSI across the socioeconomic spectrum should be prioritized to improve short bowel syndrome outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.